Results 221 to 230 of about 21,353 (254)

MS treatment: Postmarketing studies

Journal of the Neurological Sciences, 2007
Multiple sclerosis (MS) is an inflammatory chronic demyelinating disease. Nowadays, there are several registered drugs aimed to control the disease activity. Because these drugs are given parenterally for years, it is of utmost importance to attain maximum adherence to treatment through close and permanent care of patients.
openaire   +2 more sources

Postmarketing Surveillance: Beyond medWatch

JAMA: The Journal of the American Medical Association, 1993
To the Editor. —As one who has actively participated in adverse effects surveillance over the past 10 years, 1,2 I wish to applaud the new Food and Drug Administration (FDA)MEDWATCHinitiative. 3 The FDA commissioner and his staff are to be congratulated on recognizing that major efforts must be made to heighten awareness of the importance of reporting
openaire   +2 more sources

Postmarketing surveillance for drug abuse

Drug and Alcohol Dependence, 2003
Assessing actual abuse of prescribed medications requires postmarketing surveillance. In this article we discuss general systems of postmarketing surveillance that exist as of the end of 2002 in the United States and two medication-specific surveillance systems that were devised and tested.
Cynthia L, Arfken, Theodore J, Cicero
openaire   +2 more sources

Alosetron Postmarketing Experience

Clinical Pharmacology & Therapeutics, 2003
Clinical Pharmacology & Therapeutics (2003) 73, P34–P34; doi:
A.C. Mackey, A. Brinker, J. Beitz, S. Kress   +3 more
openaire   +1 more source

Postmarketing Follow-up

JAMA: The Journal of the American Medical Association, 1979
THERE is a general but strongly held view that, after drugs are marketed, additional epidemiologic information is needed on their clinical effects, particularly adverse effects. This notion is based soundly on the limited size and scope of the clinical experience with a drug before marketing.
openaire   +1 more source

Techniques of Postmarketing Surveillance

Medical Toxicology, 1986
While there are many systems available for postmarketing surveillance today, none is ideal for every situation. Recent progress has been made through computerised data bases which allows for rapid identification of patients with diseases or drugs of interest. Careful planning, with attention to the relative strengths and weaknesses of each, will permit
J L, Carson, B L, Strom
openaire   +2 more sources

Assessing risk in postmarketing surveillance

Journal of Biopharmaceutical Statistics, 1991
We need to find some way to assess the probability of risk for individuals taking medications for a prolonged period of time either singly or, as is usually more likely, in combinations. It is not possible to perform detailed, controlled studies for all combinations of drugs, not even those most commonly administered.
P B, Cerrito, J C, Cerrito
openaire   +2 more sources

Postmarketing surveillance.

The Canadian journal of hospital pharmacy, 1987
Postmarketing surveillance (PMS) studies allow for the systematic and comprehensive monitoring of the beneficial and harmful effects of prescription drugs as well as their usage patterns. The objectives of PMS are to assess the uses and effects of new drugs under conditions of customary clinical use.
openaire   +1 more source

Drug Postmarketing Studies

JAMA, 2013
Mwango, Kashoki, Cathryn, Lee, John, Jenkins   +2 more
openaire   +2 more sources

Cefmetazole postmarketing surveillance in Japan

Journal of Antimicrobial Chemotherapy, 1989
The Sankyo Company Ltd had conducted a postmarketing surveillance programme on cefmetazole sodium since its marketing introduction in Japan. Two data collection approaches were used: a survey in which participating physicians provided complete information on all their patients who received cefmetazole for treatment of infection, and two voluntary ...
openaire   +2 more sources